{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040786","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.587549+00:00","generated_at":"2026-06-08T03:34:02.936216+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"RenovoRx Q3 net loss narrows to $1.4M on warrant gain; TIGeR-PaC trial advances","bullets":["Net loss of $1.4M vs $2.1M YoY; includes $1.5M gain on fair value of common warrants.","Cash and equivalents $3.2M as of Sept 30, 2023; shares outstanding 10.7M.","R&D expense $1.6M, up 100% YoY, driven by Phase III TIGeR-PaC trial costs.","Phase III TIGeR-PaC trial for pancreatic cancer continues after interim analysis recommended continuation.","Collaboration with Imugene to expand TAMP platform into immunotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040786","json":"https://secwatch.observer/filing/0001493152-23-040786.json","markdown":"https://secwatch.observer/filing/0001493152-23-040786.md","text":"https://secwatch.observer/filing/0001493152-23-040786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223040786/0001493152-23-040786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223040786/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:34:02.936216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}